1. Home
  2. Research
  3. Research Groups
  4. Molecular Pathology of Cancer Group

Molecular Pathology of Cancer Group

Search for publications

Only original articles, editorials, guidelines.

  • Martín M, Guerrero-Zotano AL, Pérez-López ME, Ruiz-Borrego M, Martinez Jañez N, Chacón JI, Gil-Gil M, Andrés R, Bermejo B, Sánchez-Rovira P, Del Barco S, Ponce JJ, Fernandez I, Martínez de Dueñas E, Hinojo-Gonzále C, González M, García-Garre E, Hernando B, de la Haba-Rodriguez J, Álvarez IM, González-Santiago S, Garcia-Saenz JA, Santaballa A, Casas M, Bezares S, Caballero R, Rojo F, Alba E.

    Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast Cancer.

    CLINICAL CANCER RESEARCH . 32(5): 850-858. Number of citations: 4

    [doi:10.1158/1078-0432.CCR-25-2435]

  • Ruz-Caracuel I, Rosell A, Geryková L, Gama JM, Alonso-Gordoa T, Rodríguez-Villena A, Almeida R, Rosas M, Martínez-Hernández R, Martins MJ, Ryska A, Eloy C, Palacios J.

    Multi-center Assessment of DLL3 Expression by Immunohistochemistry in Medullary Thyroid Carcinoma

    ENDOCRINE PATHOLOGY . 36(1): 49-49. Number of citations: 3

    [doi:10.1007/s12022-025-09894-9]

  • Araujo-Castro M, Menéndez Torre E, Aida CL, García-Centeno R, González L, Idrobo C, Achote E, Irigaray Echarri A, Rodríguez-Argulló MDM, Paja M, Guerrero-Pérez F, Castaño JP, Dolores Ollero García M, Novo-Rodríguez C, Tenorio-Jimenéz C, Villar-Taibo R, Bernabeu I, Díaz-López E, Calatayud M, Alvarez-Escola C, Martín-Rojas P, Recio-Córdova JM, Aulinas A, Asla Roca Q, Aviles MD, López Mezquita E, Fernández Argüeso M, González Molero I, Ruz-Caracuel I, Aldecoa I, García J, Martínez-Sáez E, Hanzu F, Marazuela M, Puig-Domingo M, Biagetti B.

    Validation and Limitations of the PANOMEN-3 Predictive Model for Tumor Recurrence and Progression in Pituitary Tumors

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM . 110(12): 3391-3399. Number of citations: 13

    [doi:10.1210/clinem/dgaf252]

  • Biagetti B, Cardona-Arias A, Torre EM, Aulinas A, Ruz-Caracuel I, Centeno RG, González L, Echarri AI, Rodríguez MDM, Paja M, Guerrero-Pérez F, Castaño JP, García MDO, Novo-Rodríguez C, Tenorio-Jimenéz C, Villar-Taibo R, Bernabéu I, Díaz-López E, Calatayud M, Alvarez-Escola C, Rojas-Marcos PM, Recio-Córdova JM, Lozano-Aida C, Roca QA, Aviles MD, Mezquita EL, Argueso MF, Molero IG, Alberoa I, Idrobo C, Achote E, Martínez-Sáez E, Marazuela M, Puig-Domingo M, Hanzu F, Araujo-Castro M.

    Predictors of progression after surgery in non-functioning pituitary macroadenomas: a Spanish multicenter study

    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION . 48(12): 2857-2867. Number of citations: 5

    [doi:10.1007/s40618-025-02674-6]

  • Martínez-Hernández R, Méndez-García FF, Serrano-Somavilla A, Sacristán-Gómez P, Sánchez de la Blanca N, Sampedro-Núñez M, Navas-Moreno V, Sebastián-Valles F, Fernández-Alen JA, Biagetti B, Ruz-Caracuel I, Araujo-Castro M, Puig-Domingo M, Marazuela M.

    Clinical and Pathological Spectrum of Acromegaly: Distinguishing GH PitNETs, Mammosomatotrophs, and Mixed Tumors

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM . : . Number of citations: 3

    [doi:10.1210/clinem/dgaf634]

  • Capdevila J, Hernando J, Molina-Cerrillo J, Benavent Viñuales M, Garcia-Carbonero R, Teulé A, Custodio A, Jimenez-Fonseca P, Lopez C, Hierro C, Carmona-Bayonas A, Alonso V, Llanos M, Sevilla I, Garcia-Alvarez A, Alonso-Gordoa T, Gallego Jiménez I, Antón-Pascual B, Modrego Sánchez A, Grande E.

    Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)

    CLINICAL CANCER RESEARCH . 31(22): 4655-4663. Number of citations: 4

    [doi:10.1158/1078-0432.CCR-25-2143]

  • Martinez-Jañez N, García-Saenz JÁ, Pernas S, Bermejo B, Morales S, Guerra J, Silva J, Manso L, Ciruelos E, Tolosa P, Sánchez-Bayona R, Alva M, Calabuig-Fariñas S, Gallach S, Muinelo-Romay L, Piñeiro-Yáñez E, Caleiras E, Bueno MJ, Mouron S, Quintela-Fandino M.

    Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations

    npj Precision Oncology . 9(1): 343-343. Number of citations: 4

    [doi:10.1038/s41698-025-01106-1]

  • Carmona-Bayonas A, Álvarez Escola C, Ballester Navarro I, Hernando Cubero J, Mangas Cruz MÁ, Garcia-Centeno R, Iglesias C, García-Donas J, Picón MJ, Paja M, González Batanero L, García L, Alonso Gordoa T, López C, Hanzu F, Martínez Trufero J, Febrero Sánchez B, Saiz López P, Blanco Carrera C, Ramón Y Cajal T, Veiguela B, Gressani O, Valdés N, Jimenez-Fonseca P.

    Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM . 110(11): 3155-3167. Number of citations: 3

    [doi:10.1210/clinem/dgaf082]

  • Smith M, Piulats J, Todenhöfer T, Lee JL, Arija JA, Mazilu L, Azad A, Alonso-Gordoa T, McGovern U, Choudhury A, Horvath L, Ye D, Han W, Suzuki H, Uemura H, McKay R, Ades S, Fléchon A, Pieczonka C, Fernandes MS, Hulstijn M, Lithio A, Nacerddine K, Agarwal N.

    Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

    LANCET ONCOLOGY . 26(11): 1489-1500. Number of citations: 3

    [doi:10.1016/S1470-2045(25)00475-9]

  • Madariaga A, Cots M, Hierro C, Robles C, Garrido S, Barretina-Ginesta MP, Serrano A, Serena M, Salcedo P, Mariátegui N, Guerra E.

    Needs and opportunities for improvement in the management and monitoring of gynaecological cancer in Spain

    Clinical & Translational Oncology . : . Number of citations: 1

    [doi:10.1007/s12094-025-04127-1]

  • Lopez-Janeiro A, Brizzi E, Ruz-Caracuel I, Alexandru R, de Andrea C, Berjón A, Yebenes L, Mendiola M, Heredia-Soto V, Montero-Calle A, Barderas R, de Los Rios V, Redondo A, Pelaez-Garcia A, Hardisson D.

    The Proteomic Landscape of CTNNB1 Mutated Low-Grade Early-Stage Endometrial Carcinomas

    Cells . 14(21): . Number of citations: 2

    [doi:10.3390/cells14211676]

  • Martínez-Puente N, Ruz-Caracuel I, Leandro-García LJ, Pian-Arias H, Vega-Corral Z, Letón R, Radu R, Berrizbeitia M, Mellid S, Reglero C, Salazar-Hidalgo ME, Arroba E, Díaz-Talavera A, Marazuela M, Benito-Berlinches A, González-García I, Campos-Mena S, Lozano-Escario MD, Guadalix S, Calatayud M, Pérez-Campos A, Lahera M, Cascón A, Galofré JC, Currás-Freixes M, Caleiras EJ, Valderrabano P, Robledo M, Montero-Conde C.

    Expression of Homo Sapiens (Hsa)-miR-139-5p as a Clinically Feasible Prognostic Marker for Differentiated Thyroid Cancer

    LABORATORY INVESTIGATION . 105(10): 104199-104199.

    [doi:10.1016/j.labinv.2025.104199]

  • Servitja S, Castro-Henriques M, Álvarez-Busto I, Díez-Franco C, Medina-Castillo A, Algarra-García MA, López-Miranda E, Lario-Martínez M, Luengo-Alcázar MI, Borregón M, Davó A, Gasull-Delgado A, Roque-García S, Gonzaga-López A, Poveda-Ferriols JM, Pascal S, Mitroi-Marinescu AM, García-Escolano M, Fernández-Carvajal A, Ferrándiz-Huertas C, Ferrer-Montiel A.

    A topical nociceutical formulation ameliorates chemotherapy-induced peripheral neuropathy: a pilot randomized clinical study

    Clinical & Translational Oncology . 28(3): 1040-1048. Number of citations: 2

    [doi:10.1007/s12094-025-04062-1]

  • Soria A, Díaz A, Iruzubieta P, Martín-Mateos R, Salcedo-Allende MT, Jiménez-Masip A, Fuster-Anglada C, Arias-Loste MT, Perna C, El Maimouni C, Pericas JM, Ferrer-Gómez A, González CJ, Muñoz-Martínez S, Padilla M, Crespo J, Calixto Z, Sabiote C, Albillos A, Cervera M, Olivas I, Arvaniti P, Hernández-Évole H, Jiménez-Esquivel N, Gratacós-Ginès J, Juanola A, Pose E, Coll M, Nadal R, Pérez-Guasch M, Fabrellas N, Ginès P, Londoño MC, Graupera I.

    Autoantibodies are associated with worse outcomes in MASLD

    JHEP Reports . 7(10): 101470-101470. Number of citations: 3

    [doi:10.1016/j.jhepr.2025.101470]

  • Konstantinopoulos PA, Kim JW, Freyer G, Lee JY, Gaba L, Grisham RN, Colombo N, Wu X, Sehouli J, Cruz F, Cibula D, Monk BJ, Nyvang GB, Friedlander M, Lorusso D, Van Nieuwenhuysen E, Malik R, Glasspool R, Marth C, Leary A, Cortés-Salgado A, Zamagni C, Marmé F, Sufliarsky J, Hinson P, Zuradelli M, Wang C, Su F, Paule I, Miller M, Matulonis UA, González-Martín A.

    Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation

    JOURNAL OF CLINICAL ONCOLOGY . 43(26): 2908-2917. Number of citations: 5

    [doi:10.1200/JCO-25-00225]

  • Eskander RN, Corr B, Cibula D, Tan DSP, Cloven N, Guerra E, Hasegawa K, Myers T, You B, Makker V, Zagouri F, Gien LT, Bartoletti M, Mallen A, Woelber L, Mocci S, Komatsubara K, Ma L, Colombo N.

    A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER . : 102654-102654. Number of citations: 2

    [doi:10.1016/j.ijgc.2025.102654]

  • Quindós-Varela M, Soto de Prado-Otero D, Gallego A, García Y, Guerra E, Estévez-García P, Barretina-Ginesta MP, Borraz P, González-Martín A, Rubio MJ.

    Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain: The OVOC Study

    Oncology and Therapy . 13(3): 631-648.

    [doi:10.1007/s40487-025-00347-1]

  • Massari F, Mollica V, Kopp RM, Grande E, Fiala O, Kanesvaran R, Li H, Schieber TJ, Juan Fita MJ, Poprach A, Lolli C, Bourlon MT, de Liaño AG, Grillone F, Sunela K, Rizzo A, Ghosn M, Cerbone L, Taha T, Ürün Y, Molina-Cerrillo J, Alonso-Gordoa T, Lenci E, Martin IO, Abu-Sini H, Rescigno P, Bhuva D, Fay AP, Conteduca V, Yildirim A, Rosellini M, Akova U, Tassinari E, Bölek H, Soares A, Marques Monteiro FS, Buti S, Bilen MA, Santoni M.

    Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study

    European Urology Focus . 11(5): 736-746. Number of citations: 8

    [doi:10.1016/j.euf.2025.05.020]